Fiche centre
Peking University Third Hospital
Beijing — China
Essais liés27clinical trials
VilleBeijinglocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05152147
Essais cliniques associés
27| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Maridebart cafraglutide | Insuffisance cardiaque | Phase 3 | NCT07037459 | MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING |
| Selatogrel | Maladie coronarienne | Phase 3 | NCT04957719 | SOS-AMI — Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | ENROLLING_BY_INVITATION |
| BI 690517 | Maladie rénale chronique | Phase 3 | NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | ACTIVE_NOT_RECRUITING |
| Tenecteplase | Accident vasculaire cérébral | Phase 3 | NCT07361302 | TENACITY — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | RECRUITING |
| Finerenone | Insuffisance cardiaque | Phase 3 | NCT07575672 | FINE-VALUE — Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure | RECRUITING |
| Efgartigimod PH20 SC | Myopathies | Phase 3 | NCT05979441 | ALKIVIA+ — A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | ENROLLING_BY_INVITATION |
| anti-CD19 CAR T cell therapy | SEP | Phase 1/2 | NCT06828042 | Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases | RECRUITING |
| IBI301 | SEP | Phase 1 | NCT02945215 | A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients | COMPLETED |
| Test drug CB03-154 5mg group | Sclérose latérale amyotrophique | Phase 2/3 | NCT07082192 | A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | RECRUITING |
| BCT301 | Lupus | Phase 1 | NCT07301164 | Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases | RECRUITING |
| BR005-036C | Migraine | Phase 3 | NCT07835152 | Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults | NOT_YET_RECRUITING |
| Zanidatamab | Parkinson | Phase 3 | NCT05152147 | HERIZON-GEA-01 — A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | ACTIVE_NOT_RECRUITING |
| Rituximab IV | SEP | Phase 2 | NCT04660799 | A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) | COMPLETED |
| Prizloncabtagene Autoleucel | SEP | Phase 1/2 | NCT05800977 | ELEVATION — A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma | RECRUITING |
| LY4298445 | Lupus | Phase 1 | NCT07276958 | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) | RECRUITING |
| BR005-036C | Migraine | Phase 2/3 | NCT07792681 | Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults | RECRUITING |
| LY4405094 | Alzheimer | Phase 1 | NCT07787169 | A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease | RECRUITING |
| PF-06821497 | Cancer | Phase 3 | NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | RECRUITING |
| Vicadrostat | Hypertension | Phase 3 | NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING |
| Yangxue Qingnao Granules (Pills) | Migraine | À vérifier | NCT05334927 | CHAIRS — China HeadAche DIsorders RegiStry | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT07571161 | Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease | RECRUITING |
| Tofersen | Sclérose latérale amyotrophique | Phase 4 | NCT07223723 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| JS010 injection | Migraine | Phase 1 | NCT06158737 | A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects | COMPLETED |
| Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis | Sclérose latérale amyotrophique | À vérifier | NCT04455542 | Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis | COMPLETED |
| Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) | Sclérose latérale amyotrophique | À vérifier | NCT04454892 | Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) | RECRUITING |
| Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) | Sclérose latérale amyotrophique | Phase 1 | NCT07118319 | The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis | RECRUITING |